Outcome of Subclinical Antibody-Mediated Rejection in Kidney Transplant Recipients with Preformed Donor-Specific Antibodies

Loupy A, Suberbielle-Boissel C, Hill GS, Lefaucheur C, Anglicheau D, Zuber J, Martinez F, Thervet E, Mejean A, Charron D, Duong van Huyen JP, BrunevalP, Legendre C, Nochy D



CDC-XM negative patients with preformed DSA have significantly higher rates of AMR compared with DSA negative patients (19% vs. 0%, p<0.001), and also exhibit significantly lower 4-year graft survival (86.2% vs. 96.2%, p=0.01)